Annual accounts receivable:
$9.01B+$130.00M(+1.46%)Summary
- As of today (May 30, 2025), BMY annual accounts receivable is $9.01 billion, with the most recent change of +$130.00 million (+1.46%) on December 31, 2024.
- During the last 3 years, BMY annual accounts receivable has risen by +$1.03 billion (+12.95%).
- BMY annual accounts receivable is now at all-time high.
Performance
BMY Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$9.06B+$51.00M(+0.57%)Summary
- As of today (May 30, 2025), BMY quarterly accounts receivable is $9.06 billion, with the most recent change of +$51.00 million (+0.57%) on March 31, 2025.
- Over the past year, BMY quarterly accounts receivable has increased by +$237.00 million (+2.69%).
- BMY quarterly accounts receivable is now -7.01% below its all-time high of $9.75 billion, reached on June 30, 2024.
Performance
BMY Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
BMY Accounts receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +1.5% | +2.7% |
3 y3 years | +12.9% | +26.6% |
5 y5 years | +39.2% | +25.9% |
BMY Accounts receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +12.9% | -7.0% | +26.6% |
5 y | 5-year | at high | +39.2% | -7.0% | +35.3% |
alltime | all time | at high | +433.3% | -7.0% | +458.4% |
BMY Accounts receivable History
Date | Annual | Quarterly |
---|---|---|
Mar 2025 | - | $9.06B(+0.6%) |
Dec 2024 | $9.01B(+1.5%) | $9.01B(-3.3%) |
Sep 2024 | - | $9.32B(-4.4%) |
Jun 2024 | - | $9.75B(+10.4%) |
Mar 2024 | - | $8.83B(-0.6%) |
Dec 2023 | $8.88B(+9.0%) | $8.88B(+5.7%) |
Sep 2023 | - | $8.41B(+3.5%) |
Jun 2023 | - | $8.13B(+3.5%) |
Mar 2023 | - | $7.85B(-3.6%) |
Dec 2022 | $8.15B(+2.2%) | $8.15B(+1.6%) |
Sep 2022 | - | $8.02B(+5.7%) |
Jun 2022 | - | $7.59B(+6.0%) |
Mar 2022 | - | $7.16B(-10.3%) |
Dec 2021 | $7.98B(+10.5%) | $7.98B(+1.3%) |
Sep 2021 | - | $7.88B(+2.1%) |
Jun 2021 | - | $7.71B(+7.3%) |
Mar 2021 | - | $7.19B(-0.4%) |
Dec 2020 | $7.22B(+11.5%) | $7.22B(+6.5%) |
Sep 2020 | - | $6.78B(+1.2%) |
Jun 2020 | - | $6.70B(-7.0%) |
Mar 2020 | - | $7.20B(+11.2%) |
Dec 2019 | $6.48B(+39.7%) | $6.48B(+51.0%) |
Sep 2019 | - | $4.29B(-4.8%) |
Jun 2019 | - | $4.50B(-2.0%) |
Mar 2019 | - | $4.59B(-0.9%) |
Dec 2018 | $4.64B(+6.6%) | $4.64B(+0.3%) |
Sep 2018 | - | $4.62B(+6.9%) |
Jun 2018 | - | $4.32B(-1.2%) |
Mar 2018 | - | $4.37B(+0.6%) |
Dec 2017 | $4.35B(+15.2%) | $4.35B(+0.3%) |
Sep 2017 | - | $4.33B(+2.7%) |
Jun 2017 | - | $4.22B(+3.3%) |
Mar 2017 | - | $4.08B(+8.2%) |
Dec 2016 | $3.77B(+28.0%) | $3.77B(-1.0%) |
Sep 2016 | - | $3.81B(+3.5%) |
Jun 2016 | - | $3.69B(+9.6%) |
Mar 2016 | - | $3.36B(+14.1%) |
Dec 2015 | $2.95B(+40.4%) | $2.95B(+8.6%) |
Sep 2015 | - | $2.71B(+6.7%) |
Jun 2015 | - | $2.54B(+13.0%) |
Mar 2015 | - | $2.25B(+7.1%) |
Dec 2014 | $2.10B(+24.3%) | $2.10B(+15.2%) |
Sep 2014 | - | $1.82B(+1.3%) |
Jun 2014 | - | $1.80B(+3.3%) |
Mar 2014 | - | $1.74B(+3.1%) |
Dec 2013 | $1.69B | $1.69B(-8.1%) |
Sep 2013 | - | $1.84B(-0.6%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2013 | - | $1.85B(+2.9%) |
Mar 2013 | - | $1.80B(+5.3%) |
Dec 2012 | $1.71B(-24.1%) | $1.71B(-1.5%) |
Sep 2012 | - | $1.73B(+6.8%) |
Jun 2012 | - | $1.62B(-55.1%) |
Mar 2012 | - | $3.61B(+60.6%) |
Dec 2011 | $2.25B(-46.9%) | $2.25B(+3.2%) |
Sep 2011 | - | $2.18B(+3.1%) |
Jun 2011 | - | $2.12B(+3.4%) |
Mar 2011 | - | $2.05B(+13.4%) |
Jun 2010 | - | $1.80B(-57.3%) |
Sep 2008 | - | $4.22B(-5.5%) |
Jun 2008 | - | $4.47B(-1.6%) |
Mar 2008 | - | $4.54B(+7.1%) |
Dec 2007 | $4.24B(+30.6%) | $4.24B(+14.5%) |
Sep 2007 | - | $3.70B(+2.0%) |
Jun 2007 | - | $3.63B(+7.4%) |
Mar 2007 | - | $3.38B(+4.1%) |
Dec 2006 | $3.25B(-3.9%) | $3.25B(+10.3%) |
Sep 2006 | - | $2.94B(-11.5%) |
Jun 2006 | - | $3.33B(+2.8%) |
Mar 2006 | - | $3.24B(-4.2%) |
Dec 2005 | $3.38B(-22.8%) | $3.38B(+2.2%) |
Sep 2005 | - | $3.31B(-0.3%) |
Jun 2005 | - | $3.31B(-9.1%) |
Mar 2005 | - | $3.65B(-16.6%) |
Dec 2004 | $4.37B(+19.5%) | $4.37B(+14.8%) |
Sep 2004 | - | $3.81B(+8.6%) |
Jun 2004 | - | $3.51B(+12.9%) |
Mar 2004 | - | $3.11B(-15.1%) |
Dec 2003 | $3.66B(+23.3%) | $3.66B(+2.0%) |
Sep 2003 | - | $3.59B(+11.7%) |
Jun 2003 | - | $3.21B(+0.8%) |
Mar 2003 | - | $3.19B(+7.4%) |
Dec 2002 | $2.97B(-25.7%) | $2.97B(-17.9%) |
Sep 2002 | - | $3.62B(+4.2%) |
Jun 2002 | - | $3.47B(-3.6%) |
Mar 2002 | - | $3.60B(-9.8%) |
Dec 2001 | $3.99B(+9.0%) | $3.99B(+6.8%) |
Sep 2001 | - | $3.74B(+5.3%) |
Jun 2001 | - | $3.55B(-10.0%) |
Mar 2001 | - | $3.95B(+7.8%) |
Dec 2000 | $3.66B(+11.9%) | $3.66B(-3.2%) |
Sep 2000 | - | $3.78B(+15.6%) |
Dec 1999 | $3.27B(+2.6%) | $3.27B(+2.6%) |
Dec 1998 | $3.19B(+7.3%) | $3.19B(+1.9%) |
Sep 1998 | - | $3.13B(+5.2%) |
Dec 1997 | $2.97B | $2.97B |
FAQ
- What is Bristol-Myers Squibb annual accounts receivable?
- What is the all time high annual accounts receivable for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb annual accounts receivable year-on-year change?
- What is Bristol-Myers Squibb quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb quarterly accounts receivable year-on-year change?
What is Bristol-Myers Squibb annual accounts receivable?
The current annual accounts receivable of BMY is $9.01B
What is the all time high annual accounts receivable for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high annual accounts receivable is $9.01B
What is Bristol-Myers Squibb annual accounts receivable year-on-year change?
Over the past year, BMY annual accounts receivable has changed by +$130.00M (+1.46%)
What is Bristol-Myers Squibb quarterly accounts receivable?
The current quarterly accounts receivable of BMY is $9.06B
What is the all time high quarterly accounts receivable for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high quarterly accounts receivable is $9.75B
What is Bristol-Myers Squibb quarterly accounts receivable year-on-year change?
Over the past year, BMY quarterly accounts receivable has changed by +$237.00M (+2.69%)